Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
March 13 2023 - 07:00AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, today announced that it is aware that the Federal
Deposit Insurance Corp. has taken control of Silicon Valley Bank
(“SVB”).
Outlook Therapeutics does not hold any deposits
or investments at SVB.
About Outlook Therapeutics,
Inc.Outlook Therapeutics is a biopharmaceutical company
working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission
for ONS-5010 to treat wet AMD with a PDUFA goal date of August
29, 2023. The submission is supported by Outlook Therapeutics’ wet
AMD clinical program, which consists of three clinical trials:
NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic
bevacizumab is approved, Outlook Therapeutics expects to
commercialize it as the first and only FDA-approved ophthalmic
formulation of bevacizumab for use in treating retinal diseases
in the United States, United
Kingdom, Europe, Japan, and other markets. As part of the
Company’s multi-year commercial planning process, and in
anticipation of potential FDA approval in August
2023, Outlook Therapeutics and AmerisourceBergen have
entered into a strategic commercialization agreement to expand the
Company’s reach for connecting to retina specialists and their
patients. AmerisourceBergen will provide third-party logistics
(3PL) services and distribution, as well as pharmacovigilance
services in the United States. For more information, please
visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice President LaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023